Quincy Bioscience, LLC v. Ellishbooks

CourtCourt of Appeals for the Seventh Circuit
DecidedApril 24, 2020
Docket19-1799
StatusPublished

This text of Quincy Bioscience, LLC v. Ellishbooks (Quincy Bioscience, LLC v. Ellishbooks) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Quincy Bioscience, LLC v. Ellishbooks, (7th Cir. 2020).

Opinion

In the

United States Court of Appeals For the Seventh Circuit ____________________ No. 19‐1799 QUINCY BIOSCIENCE, LLC, Plaintiff‐Appellee, v.

ELLISHBOOKS, et al., Defendants‐Appellants. ____________________

Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 1:17‐cv‐08292 — Sharon Johnson Coleman, Judge. ____________________

ARGUED FEBRUARY 19, 2020 — DECIDED APRIL 24, 2020 ____________________

Before WOOD, Chief Judge, and FLAUM and RIPPLE, Circuit Judges. RIPPLE, Circuit Judge. Quincy Bioscience, LLC (“Quincy”) filed this civil action against Ellishbooks, related individuals, and entities (collectively “Ellishbooks”) alleging claims for trademark infringement, false advertising, dilution, and un‐ fair competition under the Lanham Act, 15 U.S.C. §§ 1114, 1125, as well as claims under Illinois statutory and common law. The operative complaint alleged that Ellishbooks en‐ 2 No. 19‐1799

gaged in the unauthorized and unlawful sale of Quincy’s products bearing the Prevagen® trademark. Ellishbooks did not file a responsive pleading to the complaint. After entry of a default judgment, the district court awarded damages and permanent injunctive relief to Quincy. Ellishbooks now challenges the district court’s judgment on several grounds. These arguments have been waived and, in any event, are meritless. We therefore affirm the judgment of the district court. I. BACKGROUND Quincy develops, markets, and sells dietary supple‐ ments, which its customers use for the support of cognitive 1 function. It packages its Prevagen® product “in a single fac‐ ing box, which contains a bottle of dietary supplements sealed with a plastic safety overwrap and a product infor‐ mation sheet. Both the box and the sheet contain valuable information regarding the product which is not present on 2 the bottle label … .” Prevagen® is marketed and sold through brick‐and‐mortar stores and on Internet websites. Quincy registered its Prevagen® trademark in 2007 and has used it continually since that time.

1 The facts are those alleged in Quincy’s first amended complaint be‐ cause, “[u]pon default, the well‐pled allegations of the complaint relating to liability are taken as true.” Wehrs v. Wells, 688 F.3d 886, 892 (7th Cir. 2012). 2 R.10 ¶15. No. 19‐1799 3

Ellishbooks, which was not authorized to sell Prevagen® products, sold dietary supplements identified as Prevagen® on Amazon.com. These products included items that (1) were in altered or damaged packaging that lacked the prod‐ uct information sheets found in Prevagen® products sold by authorized sellers; (2) lacked the appropriate purchase codes or other markings that identify the appropriately authorized retail seller of the product; and (3) contained Radio Frequen‐ cy Identification tags and security tags from retail pharmacy stores. Ellishbooks “knew or had reason to know that at least some of the PREVAGEN® products [it] sold were at one 3 time stolen from retail outlets across the country.” Quincy brought this action against Ellishbooks, alleging violations of the Lanham Act and violations of Illinois statu‐ 4 tory and common law. It sought preliminary and perma‐ nent injunctive relief to prevent Ellishbooks from using the Prevagen® mark, from using any symbol or mark calculated to represent the Prevagen® mark, and from falsely repre‐ senting that it was associated with Quincy. It also requested an accounting of any profits Ellishbooks had derived from

3 Id. ¶ 30.

4 Specifically, Count I alleged trademark infringement under 15 U.S.C. § 1114; Count II alleged false designation of origin and unfair competi‐ tion under 15 U.S.C. § 1125(a)(1)(A); Count III alleged false advertising under 15 U.S.C. § 1125(a)(1)(B); Count IV alleged dilution under 15 U.S.C. §1125(c); Count V alleged dilution under the Illinois Trademark Registration and Protection Act, 765 ILCS 1036/65; Count VI alleged un‐ fair competition under Illinois common law; Count VII alleged violation of the Illinois Uniform Deceptive Trade Practices Act, 815 ILCS 510/2; and Count VIII alleged unjust enrichment. See generally R.10. 4 No. 19‐1799

Prevagen® products. Finally, it sought damages, lost profits, statutory damages, treble damages, and attorneys’ fees. Ellishbooks did not answer the complaint, and, conse‐ 5 quently, Quincy filed a motion for entry of default. The dis‐ trict court granted Quincy’s motion. Quincy then moved for 6 entry of default judgment. Ellishbooks opposed the motion on two grounds: (1) that it had not been served properly 7 with the summons and complaint; and (2) that it listed and sold on Amazon.com goods that were “different and distinct 8 from those produced and sold by [Quincy].” With respect to the second ground, Ellishbooks stated that its “products [we]re not listed or identified as Prevagen, as alleged by [Quincy], but [we]re instead listed and sold under a different 9 name and with different packaging.” The district court granted the motion for a default judg‐ ment. It detailed the myriad ways Quincy had attempted to effectuate personal service, observed that Ellishbooks “de‐ liberately [had] obfuscated their place of business and

5 See Fed. R. Civ. P. 55(a) (“When a party against whom a judgment for affirmative relief is sought has failed to plead or otherwise defend, and that failure is shown by affidavit or otherwise, the clerk must enter the party’s default.”). 6 See Fed. R. Civ. P. 55(b)(2) (setting forth the requirements for entry of a default judgment by a court). 7 See R.23 at 2.

8 Id. at 11.

9 Id. No. 19‐1799 5

sought to evade service,” and noted that, having failed in other efforts, “Quincy mailed service to Elishbook Corpora‐ tion’s registered agent at the listed address in accordance 10 with New Jersey law.” The district court therefore conclud‐ ed that Quincy had effected “legally adequate service,” and 11 the court had personal jurisdiction over the defendants. The district court noted that Ellishbooks also had re‐ quested that the default be vacated on substantive grounds. The court explained that, “[i]n order to have a default vacat‐ ed, a party must establish good cause for their default, quick action to correct it, and a meritorious defense to the plain‐ 12 tiff’s complaint.” Apart from its allegations about lack of service, however, Ellishbooks had “identified no circum‐ 13 stances capable of establishing good cause for [its] default.” Consequently, the district court concluded that Ellishbooks had “failed to establish that the default against [it] should be 14 vacated.” After entering a default judgment in favor of Quincy, the district court scheduled a prove‐up hearing to determine the amount of damages to be awarded. Quincy filed a motion for leave to take pre‐hearing dis‐ covery with respect to damages. On the same day, Ellish‐

10 R.28 at 3.

11 See id. at 3–4.

12 Id. at 4 (citing Parker v. Scheck Mech.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Fednav International Ltd. v. Continental Insurance
624 F.3d 834 (Seventh Circuit, 2010)
William Wehrs, Jr. v. Kevin Wells
688 F.3d 886 (Seventh Circuit, 2012)
General Parker v. Scheck Mechanical, Corp.
772 F.3d 502 (Seventh Circuit, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
Quincy Bioscience, LLC v. Ellishbooks, Counsel Stack Legal Research, https://law.counselstack.com/opinion/quincy-bioscience-llc-v-ellishbooks-ca7-2020.